Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614477 | 0.88 | CYP1A2 (0.43) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL12614478 | 0.88 | CYP1A2 (0.43) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL29400919 | 0.85 | CYP1A2 (0.38) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL3677722 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL3677719 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL2591631 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL29386517 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP2C9ALDH1A1GAALMNA | |
| SCHEMBL7490279 | 0.84 | CYP1A2 (0.45) | CYP1A2CYP2C9ALDH1A1GAALMNA | |
| SCHEMBL10347234 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2C9ALDH1A1LMNANPSR1 | |
| SCHEMBL15328407 | 0.83 | CYP1A2 (0.40) | CYP1A2CYP2C9ALDH1A1GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7235585-B2 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| EP-0804413-B1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RES CAMPAIGN TECH (GB) | 2000-05-17 | — | — | EP | disclosed |
| US-6005002-A | Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-12-21 | — | — | US | disclosed |
| EP-0804413-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022277-A1 | NITROGEN MUSTARD PRODRUGS WITH NOVEL LIPOPHILIC PROTECTING GROUPS, AND PROCESSES FOR THEIR PRODUCTION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CNDP2, PNP, APRT | CYP1A2 470/4885CYP2C9 786/4885ALDH1A1 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.